In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 650 ( 2022-06-22)
Abstract:
Infection with respiratory syncytial virus (RSV) can cause severe disease in both infants and older adults, and vaccines for RSV are essential for protecting both of these populations. Here, Phung et al . evaluated memory B cell responses elicited by a candidate RSV prefusion (pre-F)–stabilized subunit vaccine. The vaccine, DS-Cav1, elicited pre-F–specific B cell responses. A subset of these activated cells were human metapneumovirus cross-reactive B cells capable of binding the pre-F of both viruses. Together, these data support further clinical development of DS-Cav1.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abo5032
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink